Multivariate evaluation of prognostic markers in synovial sarcoma

Area of Science:

• Oncology
• Pathology
• Cancer Research

Background:

• Synovial sarcoma (SS) is an aggressive cancer with variable outcomes.
• Prognostic markers are crucial for predicting SS patient outcomes.
• Identifying reliable markers can guide treatment strategies.

Purpose of the Study:

• To evaluate clinicopathological and immunohistochemical factors as prognostic markers in synovial sarcoma.
• To assess the association of these factors with overall survival (OS) and disease-free survival (DFS).

Main Methods:

• Retrospective analysis of a single-institution cohort of 133 synovial sarcoma patients.
• Examination of clinical factors: age, sex, tumor location, AJCC stage, size, grade, and margins.
• Immunohistochemical staining for p16, p53, RB1, MYC, PTEN, β-catenin, MDM2, and Ki67.
• Multivariate Cox proportional hazard modeling for OS and DFS.

Main Results:

• Tumor location (axial vs. extremity), AJCC stage, and p16 expression were associated with worse OS.
• PTEN intensity and p53 expression correlated with improved OS.
• Location, tumor size (≥5 cm), and MYC expression were linked to inferior DFS.
• PTEN intensity was the sole marker significantly associated with improved DFS.

Conclusions:

• Location, AJCC stage, p16, p53, and PTEN expression are significant prognostic indicators for OS in SS.
• Location, tumor size, MYC, and PTEN expression significantly impact DFS in SS patients.
• These markers can aid in refining prognostic assessments and treatment planning for synovial sarcoma.